Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas

NCT04617002 · clinicaltrials.gov ↗
APPROVED_FOR_MARKETING
Status
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Jazz Pharmaceuticals